New combo therapy aims to slow advanced prostate cancer

NCT ID NCT07451795

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Mar 10, 2026 · Last updated Apr 29, 2026 · Updated 6 times

Summary

This study tests whether adding a drug called SHR-1701 to targeted radiation can help control metastatic castration-resistant prostate cancer (mCRPC). About 66 men aged 18-80 whose cancer has worsened after at least one prior treatment will receive either the combination or standard care. The main goal is to see how long the cancer stays from growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Fudan University Shanghai Cancer Center Xiamen Branch
RECRUITING

Xiamen, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Fujian Cancer Hospital
RECRUITING

Fujian, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) PROSTATE CANCER